Zining Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zining Luo has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Jiebin Xie
Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College
7 shared publications Junjie Cao
North Sichuan Medical University
5 shared publications- Tianxiang Geng
Department of Orthopedics, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University, China
3 shared publications Jiang Yu
North Sichuan Medical University, Nanchong, Sichuan, China
2 shared publicationsJunyi Lou
Medical School of Ophthalmology & Optometry, North Sichuan Medical College
2 shared publicationsMingjun Sun
North Sichuan Medical University
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1904028
Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries
Background: Chronic myeloid leukemia is commonly treated with tyrosine kinase inhibitors, and numerous clinical trials have been conducted globally. However, the overall registration distribution, trial development patterns, and public availability of trial results remain unclear. This study aimed to map the global landscape of such trials and assess the public availability of their results. Methods: This registry-based cross-sectional landscape analysis searched five major public clinical trial registries up to 19 March 2026. Results availability among eligible completed trials was assessed using registry records and a supplementary bibliographic search. Two reviewers independently screened trials, extracted data, and resolved discrepancies by adjudication. Descriptive statistical analysis was conducted using R software. We focused on completed trials finished for at least 2 years to evaluate publication. Results: A total of 125 trials were included, of which 96 (76.8%) were interventional studies and 23 (18.4%) were randomized. Trials were concentrated in the United States, Europe, China, and Australia. Most trials targeted BCR-ABL1 and were Phase II studies, whereas Phase I and Phase IV studies were less common. Among 52 eligible completed pharmacological trials, publicly identifiable results were available for 25 trials (48.1%). Among the 44 trials with reported clinical phase, results availability was 77.8% (7/9) for Phase III trials and 0% (0/4) for Phase I trials. Results availability varied descriptively across drug groups, although no drug-specific comparison remained statistically significant after adjustment for multiple testing. Conclusion: Global trials are geographically and developmentally unbalanced, with incomplete public availability of trial results. Future research should strengthen international collaboration, optimize trial phase distribution, support novel agent development, and promote timely and complete public disclosure of trial results.
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1904028
Open AccessTyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries
Background: Chronic myeloid leukemia is commonly treated with tyrosine kinase inhibitors, and numerous clinical trials have been conducted globally. However, the overall registration distribution, trial development patterns, and public availability of trial results remain unclear. This study aimed to map the global landscape of such trials and assess the public availability of their results. Methods: This registry-based cross-sectional landscape analysis searched five major public clinical trial registries up to 19 March 2026. Results availability among eligible completed trials was assessed using registry records and a supplementary bibliographic search. Two reviewers independently screened trials, extracted data, and resolved discrepancies by adjudication. Descriptive statistical analysis was conducted using R software. We focused on completed trials finished for at least 2 years to evaluate publication. Results: A total of 125 trials were included, of which 96 (76.8%) were interventional studies and 23 (18.4%) were randomized. Trials were concentrated in the United States, Europe, China, and Australia. Most trials targeted BCR-ABL1 and were Phase II studies, whereas Phase I and Phase IV studies were less common. Among 52 eligible completed pharmacological trials, publicly identifiable results were available for 25 trials (48.1%). Among the 44 trials with reported clinical phase, results availability was 77.8% (7/9) for Phase III trials and 0% (0/4) for Phase I trials. Results availability varied descriptively across drug groups, although no drug-specific comparison remained statistically significant after adjustment for multiple testing. Conclusion: Global trials are geographically and developmentally unbalanced, with incomplete public availability of trial results. Future research should strengthen international collaboration, optimize trial phase distribution, support novel agent development, and promote timely and complete public disclosure of trial results.
- Open Access
- 14 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1939348
Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer
Correction on: Zhou Y, Cao J, Zhang S, Sun M, Zhang Y, Li S, Luo Z, Wang P and Xie J (2025) Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer. Front. Oncol. 15:1683624. doi: 10.3389/fonc.2025.1683624 Missing affiliation where work was done (Note: adding present affiliations after moving is not permitted.)Affiliation [ ] was omitted from the paper. This affiliation has now been added for author (s)
- 14 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1939348
Open AccessCorrection: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer
Correction on: Zhou Y, Cao J, Zhang S, Sun M, Zhang Y, Li S, Luo Z, Wang P and Xie J (2025) Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer. Front. Oncol. 15:1683624. doi: 10.3389/fonc.2025.1683624 Missing affiliation where work was done (Note: adding present affiliations after moving is not permitted.)Affiliation [ ] was omitted from the paper. This affiliation has now been added for author (s)
- Open Access
- 5 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1680115
Application of JAK inhibitors in the treatment of rheumatoid arthritis: a systematic analysis based on clinical trial databases and registries
Objective: To systematically analyze 2014–2025 global clinical trial data of Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA), clarify their R&D evolution, regional characteristics, efficacy and safety profiles, and provide evidence-based support for optimizing RA therapeutic strategies. Methods: Trials were retrieved from 16 international registries using PubMed MeSH and Embase Emtree terms, then screened per PRISMA guidelines for compliance with 2010 ACR/EULAR RA criteria and JAK-targeted therapy. A total of 87 eligible trials were analyzed for phase, molecular target, status, drug type and geographic region. Results: China (42 trials) and the U.S. (32 trials) dominated global research, with the U.S. leading R&D and China combining independent and collaborative studies. JAK2/JAK3-targeted trials rose from 25% (2014–2018) to 62.7% (2019–2025, p < 0.01), shifting toward multi-target combinations (e.g., TYK2 + JAK1) and away from Pan-JAK agents. JAK inhibitors showed target-dependent efficacy; infections were the most common adverse events, with serious adverse event (SAE) rates of 2.91–7.37% and drug-specific safety profiles. Trial data disclosure was uneven, with gaps in investigational drug and Phase IV trial data. Conclusion: JAK inhibitors are key RA therapeutics with target-distinct efficacy and safety. Future efforts should prioritize high-quality Phase IV studies, regional subgroup analyses, head-to-head target comparisons and standardized data disclosure. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261290714 , Identifier CRD420261290714.
- 5 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1680115
Open AccessApplication of JAK inhibitors in the treatment of rheumatoid arthritis: a systematic analysis based on clinical trial databases and registries
Objective: To systematically analyze 2014–2025 global clinical trial data of Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA), clarify their R&D evolution, regional characteristics, efficacy and safety profiles, and provide evidence-based support for optimizing RA therapeutic strategies. Methods: Trials were retrieved from 16 international registries using PubMed MeSH and Embase Emtree terms, then screened per PRISMA guidelines for compliance with 2010 ACR/EULAR RA criteria and JAK-targeted therapy. A total of 87 eligible trials were analyzed for phase, molecular target, status, drug type and geographic region. Results: China (42 trials) and the U.S. (32 trials) dominated global research, with the U.S. leading R&D and China combining independent and collaborative studies. JAK2/JAK3-targeted trials rose from 25% (2014–2018) to 62.7% (2019–2025, p < 0.01), shifting toward multi-target combinations (e.g., TYK2 + JAK1) and away from Pan-JAK agents. JAK inhibitors showed target-dependent efficacy; infections were the most common adverse events, with serious adverse event (SAE) rates of 2.91–7.37% and drug-specific safety profiles. Trial data disclosure was uneven, with gaps in investigational drug and Phase IV trial data. Conclusion: JAK inhibitors are key RA therapeutics with target-distinct efficacy and safety. Future efforts should prioritize high-quality Phase IV studies, regional subgroup analyses, head-to-head target comparisons and standardized data disclosure. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261290714 , Identifier CRD420261290714.
- Open Access
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1737537
Global landscape analysis of clinical trials on gut microbiota modulation therapies for irritable bowel syndrome
Objective: Systematically analyze the global landscape of interventional clinical trials on gut microbiota modulation (GMM) therapies for irritable bowel syndrome (IBS). Methods: Searched the Trialtrove database (1998–July 2025) with the key term combination “(Disease is Autoimmune/Inflammation: Irritable Bowel Syndrome) AND (Mechanism of Action: Microbiome modulator)”, included 305 interventional trials (excluded 15 observational studies). Descriptive analysis was done via SPSS 26.0, adhering to TITAN Guidelines 2025. Results: Asia was the most active region; trials peaked in 2021, with Phase II (44.3%) and IV (33.3%) dominant. Probiotics led (single-strain: Lactobacillus/Bifidobacterium; multi-strain: Lactobacillus + Bifidobacterium), followed by fecal microbiota transplantation (FMT). IBS-D (49.6%) was the main subtype (IBS-C: 26.1%); probiotics were the most frequently studied for both, FMT for IBS-D, and prebiotics for IBS-C. Conclusion: GMM therapies for IBS are relatively mature. Personalized therapies are necessary; multiomics and emerging therapies (e.g., Akkermansia muciniphila ) will promote IBS precision medicine.
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1737537
Open AccessGlobal landscape analysis of clinical trials on gut microbiota modulation therapies for irritable bowel syndrome
Objective: Systematically analyze the global landscape of interventional clinical trials on gut microbiota modulation (GMM) therapies for irritable bowel syndrome (IBS). Methods: Searched the Trialtrove database (1998–July 2025) with the key term combination “(Disease is Autoimmune/Inflammation: Irritable Bowel Syndrome) AND (Mechanism of Action: Microbiome modulator)”, included 305 interventional trials (excluded 15 observational studies). Descriptive analysis was done via SPSS 26.0, adhering to TITAN Guidelines 2025. Results: Asia was the most active region; trials peaked in 2021, with Phase II (44.3%) and IV (33.3%) dominant. Probiotics led (single-strain: Lactobacillus/Bifidobacterium; multi-strain: Lactobacillus + Bifidobacterium), followed by fecal microbiota transplantation (FMT). IBS-D (49.6%) was the main subtype (IBS-C: 26.1%); probiotics were the most frequently studied for both, FMT for IBS-D, and prebiotics for IBS-C. Conclusion: GMM therapies for IBS are relatively mature. Personalized therapies are necessary; multiomics and emerging therapies (e.g., Akkermansia muciniphila ) will promote IBS precision medicine.
- Open Access
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1683624
Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer
The global incidence of thyroid cancer has increased significantly, and patients with advanced, recurrent, or radioiodine-refractory disease face a severe shortage of effective treatment options. The RET proto-oncogene serves as a key driver in the development of thyroid cancer, and its alterations are closely associated with highly aggressive tumor subtypes. Although the emergence of highly selective RET inhibitors (such as selpercatinib and pralsetinib) has revolutionized the treatment landscape, their complete clinical development pathway, rational combination strategies, and future research priorities still require systematic clarification. Understanding the development trends of these drugs is important for guiding clinical decision-making, optimizing trial design, and accelerating new drug development. We searched 16 clinical trial registries, and identified 18 studies registered up to 21 March 2025. Our analysis revealed that among the 18 eligible trials, the majority were Phase 1/2 studies. Selpercatinib and pralsetinib are the most frequently studied RET inhibitors. Notably, research on next-generation RET inhibitors as monotherapy approaches (e.g., LOXO-260, enbezotinib, SY-5007 and TY-1091) is currently underway. Additionally, combination regimens incorporating these inhibitors with agents such as ¹³¹I, recombinant human thyroid-stimulating hormone (rhTSH), and anti-programmed cell death protein 1 (anti-PD-1) antibodies are becoming an increasingly important area of investigation. While selective RET inhibitors have demonstrated therapeutic potential, concerns regarding drug resistance and toxicity persist. Therefore, future strategies should prioritize the development of next-generation inhibitors and the optimization of combination regimens to improve outcomes for RET -altered thyroid cancer patients.
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1683624
Open AccessReview and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer
The global incidence of thyroid cancer has increased significantly, and patients with advanced, recurrent, or radioiodine-refractory disease face a severe shortage of effective treatment options. The RET proto-oncogene serves as a key driver in the development of thyroid cancer, and its alterations are closely associated with highly aggressive tumor subtypes. Although the emergence of highly selective RET inhibitors (such as selpercatinib and pralsetinib) has revolutionized the treatment landscape, their complete clinical development pathway, rational combination strategies, and future research priorities still require systematic clarification. Understanding the development trends of these drugs is important for guiding clinical decision-making, optimizing trial design, and accelerating new drug development. We searched 16 clinical trial registries, and identified 18 studies registered up to 21 March 2025. Our analysis revealed that among the 18 eligible trials, the majority were Phase 1/2 studies. Selpercatinib and pralsetinib are the most frequently studied RET inhibitors. Notably, research on next-generation RET inhibitors as monotherapy approaches (e.g., LOXO-260, enbezotinib, SY-5007 and TY-1091) is currently underway. Additionally, combination regimens incorporating these inhibitors with agents such as ¹³¹I, recombinant human thyroid-stimulating hormone (rhTSH), and anti-programmed cell death protein 1 (anti-PD-1) antibodies are becoming an increasingly important area of investigation. While selective RET inhibitors have demonstrated therapeutic potential, concerns regarding drug resistance and toxicity persist. Therefore, future strategies should prioritize the development of next-generation inhibitors and the optimization of combination regimens to improve outcomes for RET -altered thyroid cancer patients.
- Open Access
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Dental Medicine
- Vol. 6, 1689513
Clinical trial landscape for guided bone regeneration: trend analysis and future perspectives
Aim: This study aims to comprehensively analyse the developmental progress of bone graft materials and barrier membranes in the field of oral-maxillofacial bone regeneration, with a particular emphasis on emerging therapeutic approaches for bone regeneration. Materials and methods: This study systematically searched 16 clinical trial registries using key terms such as “bone regeneration” and “osteoconduction” to identify relevant trials. The retrieved studies were then categorized and analysed on the basis of registration year, research phase, material/drug classification, and geographical distribution. Results: In the field of bone graft materials and barrier membranes, clinical trials involving synthetic bone graft materials ( N = 90) and xenogeneic bone graft materials ( N = 67) have been the most common. In the category of barrier membranes, collagen membranes still dominate ( N = 53), whereas other natural membranes, such as amniotic and chorionic membranes, are in clinical trials. Resorbable polyester membranes ( N = 24), titanium mesh ( N = 13) and nonresorbable polytetrafluoroethylene membranes ( N = 11) are commonly studied barrier membranes. Platelet-rich fibrin (PRF) ( N = 71) is the most frequently used type of bioactive adjuvant. Some trials have explored the synergistic effects of statins ( N = 17) and plant-derived active extracts ( N = 16). Conclusion: Research on bone regeneration is undergoing a paradigm shift from the conventional “bone graft + barrier membrane” approach to integrated multicomponent strategies. These advanced strategies combine tunable biodegradable scaffolds, growth factors, and small-molecule drugs to achieve personalized and cost-effective bone defect repair. Future research priorities will focus on optimizing material degradation kinetics and spatial maintenance properties to enhance clinical outcomes.
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Dental Medicine
- Vol. 6, 1689513
Open AccessClinical trial landscape for guided bone regeneration: trend analysis and future perspectives
Aim: This study aims to comprehensively analyse the developmental progress of bone graft materials and barrier membranes in the field of oral-maxillofacial bone regeneration, with a particular emphasis on emerging therapeutic approaches for bone regeneration. Materials and methods: This study systematically searched 16 clinical trial registries using key terms such as “bone regeneration” and “osteoconduction” to identify relevant trials. The retrieved studies were then categorized and analysed on the basis of registration year, research phase, material/drug classification, and geographical distribution. Results: In the field of bone graft materials and barrier membranes, clinical trials involving synthetic bone graft materials ( N = 90) and xenogeneic bone graft materials ( N = 67) have been the most common. In the category of barrier membranes, collagen membranes still dominate ( N = 53), whereas other natural membranes, such as amniotic and chorionic membranes, are in clinical trials. Resorbable polyester membranes ( N = 24), titanium mesh ( N = 13) and nonresorbable polytetrafluoroethylene membranes ( N = 11) are commonly studied barrier membranes. Platelet-rich fibrin (PRF) ( N = 71) is the most frequently used type of bioactive adjuvant. Some trials have explored the synergistic effects of statins ( N = 17) and plant-derived active extracts ( N = 16). Conclusion: Research on bone regeneration is undergoing a paradigm shift from the conventional “bone graft + barrier membrane” approach to integrated multicomponent strategies. These advanced strategies combine tunable biodegradable scaffolds, growth factors, and small-molecule drugs to achieve personalized and cost-effective bone defect repair. Future research priorities will focus on optimizing material degradation kinetics and spatial maintenance properties to enhance clinical outcomes.
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (10) , 7168-7180
Comparative effectiveness of colonic stenting alone and with neoadjuvant chemotherapy for patients with left-sided obstructive colon cancer: a meta-analysis
Background: The effective management of acute left-sided obstructive colon cancer (LSOCC) remains challenging. This meta-analysis compared the short-term and long-term outcomes between two prevalent treatment approaches: selective surgery following colonic stenting (CS) and colonic stenting combined with neoadjuvant chemotherapy (CS-NAC). Methods: We conducted a comprehensive literature search of databases, including PubMed and Web of Science, covering the period from January 2000 to May 2025. Relevant studies comparing CS with CS-NAC were identified and analyzed. Both the short-term and long-term outcomes of the two treatment strategies were evaluated. The meta-analysis calculated pooled odds ratios (ORs), mean differences (MDs), and 95% confidence intervals (95% CIs). This study is registered with PROSPERO (registration number: CRD42024580176). Results: Seven studies were included in the meta-analysis. Compared with the CS strategy, the CS-NAC strategy demonstrated significantly better short-term outcomes, including higher rates of laparoscopic surgery, lower intraoperative stoma rates, fewer overall postoperative adverse events, shorter operative times, and shorter postoperative hospital stays. However, no significant differences were observed between the two strategies in terms of stent-related complications or specific short-term adverse events, including postoperative incision infection rates, anastomotic leakage rates, and pulmonary infection rates. Furthermore, compared with the CS strategy, the CS-NAC strategy significantly improved both 3-year disease-free survival and overall survival. Conclusion: Compared with CS alone, the CS-NAC treatment strategy improves laparoscopic surgery rates and 3-year survival outcomes without increasing the risk of certain postoperative adverse events.
- 15 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (10) , 7168-7180
Open AccessComparative effectiveness of colonic stenting alone and with neoadjuvant chemotherapy for patients with left-sided obstructive colon cancer: a meta-analysis
Background: The effective management of acute left-sided obstructive colon cancer (LSOCC) remains challenging. This meta-analysis compared the short-term and long-term outcomes between two prevalent treatment approaches: selective surgery following colonic stenting (CS) and colonic stenting combined with neoadjuvant chemotherapy (CS-NAC). Methods: We conducted a comprehensive literature search of databases, including PubMed and Web of Science, covering the period from January 2000 to May 2025. Relevant studies comparing CS with CS-NAC were identified and analyzed. Both the short-term and long-term outcomes of the two treatment strategies were evaluated. The meta-analysis calculated pooled odds ratios (ORs), mean differences (MDs), and 95% confidence intervals (95% CIs). This study is registered with PROSPERO (registration number: CRD42024580176). Results: Seven studies were included in the meta-analysis. Compared with the CS strategy, the CS-NAC strategy demonstrated significantly better short-term outcomes, including higher rates of laparoscopic surgery, lower intraoperative stoma rates, fewer overall postoperative adverse events, shorter operative times, and shorter postoperative hospital stays. However, no significant differences were observed between the two strategies in terms of stent-related complications or specific short-term adverse events, including postoperative incision infection rates, anastomotic leakage rates, and pulmonary infection rates. Furthermore, compared with the CS strategy, the CS-NAC strategy significantly improved both 3-year disease-free survival and overall survival. Conclusion: Compared with CS alone, the CS-NAC treatment strategy improves laparoscopic surgery rates and 3-year survival outcomes without increasing the risk of certain postoperative adverse events.
- Open Access
- 19 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (9) , 6397-6411
Robotic versus laparoscopic total gastrectomy for gastric cancer: a systematic review and meta-analysis of perioperative and oncologic outcomes
Background: While robotic total gastrectomy (RTG) has gained traction in minimally invasive gastric cancer surgery, high-level evidence comparing its efficacy with laparoscopic total gastrectomy (LTG) remains limited. This systematic review and meta-analysis aimed to comprehensively evaluate the comparative efficacy and safety of RTG versus LTG in gastric cancer patients, thereby informing evidence-based surgical decision-making. Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases from inception until November 2024 for comparative studies of RTG and LTG. Perioperative outcomes (intraoperative blood loss, severe complications [Clavien–Dindo grade ≥3], abdominal infection rates, postoperative hospitalization) and oncologic parameters (retrieved lymph nodes, 3-year overall survival [OS], disease-free survival [DFS]) were analyzed. Risk ratios and weighted mean differences (WMD) with 95% confidence intervals were calculated. Protocol registered with PROSPERO. Results: The results revealed that RTG significantly reduced severe complications (CD ≥3), abdominal infection, intraoperative blood loss, and postoperative hospital stay compared to LTG. Additionally, RTG led to an increased number of retrieved lymph nodes. However, no significant differences were observed in 3-year OS and DFS between RTG and LTG, consistent with findings from other types of gastrectomy. The subgroup analysis demonstrated that the use of linear staplers was more effective in reducing severe complications and postoperative hospital stay. Conclusion: RTG confers superior perioperative safety profiles compared to LTG while maintaining equivalent oncologic outcomes. The technical advantages of robotic platforms – particularly enhanced instrument maneuverability in narrow spaces – may explain reduced intraoperative trauma and complication risks. These findings support RTG as a viable option for centers with robotic expertise, though cost-effectiveness analyses remain warranted.
- 19 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (9) , 6397-6411
Open AccessRobotic versus laparoscopic total gastrectomy for gastric cancer: a systematic review and meta-analysis of perioperative and oncologic outcomes
Background: While robotic total gastrectomy (RTG) has gained traction in minimally invasive gastric cancer surgery, high-level evidence comparing its efficacy with laparoscopic total gastrectomy (LTG) remains limited. This systematic review and meta-analysis aimed to comprehensively evaluate the comparative efficacy and safety of RTG versus LTG in gastric cancer patients, thereby informing evidence-based surgical decision-making. Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases from inception until November 2024 for comparative studies of RTG and LTG. Perioperative outcomes (intraoperative blood loss, severe complications [Clavien–Dindo grade ≥3], abdominal infection rates, postoperative hospitalization) and oncologic parameters (retrieved lymph nodes, 3-year overall survival [OS], disease-free survival [DFS]) were analyzed. Risk ratios and weighted mean differences (WMD) with 95% confidence intervals were calculated. Protocol registered with PROSPERO. Results: The results revealed that RTG significantly reduced severe complications (CD ≥3), abdominal infection, intraoperative blood loss, and postoperative hospital stay compared to LTG. Additionally, RTG led to an increased number of retrieved lymph nodes. However, no significant differences were observed in 3-year OS and DFS between RTG and LTG, consistent with findings from other types of gastrectomy. The subgroup analysis demonstrated that the use of linear staplers was more effective in reducing severe complications and postoperative hospital stay. Conclusion: RTG confers superior perioperative safety profiles compared to LTG while maintaining equivalent oncologic outcomes. The technical advantages of robotic platforms – particularly enhanced instrument maneuverability in narrow spaces – may explain reduced intraoperative trauma and complication risks. These findings support RTG as a viable option for centers with robotic expertise, though cost-effectiveness analyses remain warranted.
- 5 December 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 19 (12) , e94-e95
Strengthening the Evidence: Expanding Research on Passive Smoking and Lung Cancer
- 5 December 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 19 (12) , e94-e95
Strengthening the Evidence: Expanding Research on Passive Smoking and Lung Cancer
- 28 August 2024
- Published by Elsevier in Annals of Oncology
- Vol. 35 (11) , 1064-1065
Efficacy rigor of neoadjuvant therapy: the role and synthesis of tumor subtype analysis. Letter to the Editor regarding ‘Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial’ by Conroy T et al.
- 28 August 2024
- Published by Elsevier in Annals of Oncology
- Vol. 35 (11) , 1064-1065
Efficacy rigor of neoadjuvant therapy: the role and synthesis of tumor subtype analysis. Letter to the Editor regarding ‘Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial’ by Conroy T et al.